PMID- 27635639
OWN - NLM
STAT- MEDLINE
DCOM- 20180725
LR  - 20200930
IS  - 1555-8576 (Electronic)
IS  - 1538-4047 (Print)
IS  - 1538-4047 (Linking)
VI  - 18
IP  - 11
DP  - 2017 Nov 2
TI  - Clinicopathological characteristics and survival of ALK, ROS1 and RET 
      rearrangements in non-adenocarcinoma non-small cell lung cancer patients.
PG  - 883-887
LID - 10.1080/15384047.2016.1235660 [doi]
AB  - BACKGROUND: ALK, ROS1 and RET rearrangements represent 3 most frequent fusion 
      genes in non-small cell lung cancer (NSCLC). Rearrangements of these 3 genes 
      exist predominantly in lung adenocarcinoma while rarely in non-adenocarcinoma. 
      Our objective was to explore the frequency, clinicopathological characteristics 
      and survival of ALK, ROS1 and RET rearrangements in non-adenocarcinoma NSCLC 
      patients. METHODS: ALK, ROS1 and RET rearrangements were screened by reverse 
      transcriptase polymerase chain reaction (RT-PCR) in patients with completely 
      resected non-adenocarcinoma NSCLC. All positive samples were confirmed with 
      fluorescence in situ hybridization (FISH). Survival analysis was performed with 
      Kaplan-Meier method and log-rank for comparison. RESULTS: A total of 385 patients 
      underwent complete resection, including squamous cell carcinoma (n = 245), 
      adenosquamous carcinoma (n = 85) and large cell carcinoma (n = 55). Twelve of 
      them were identified as harboring fusion genes, including ALK (n = 7), ROS1 (n = 
      3) and RET (n = 2) rearrangements. The fusion frequencies of adenosquamous, 
      squamous cell and large cell carcinomas were 8.2%, 1.6% and 1.8% respectively. 
      Their median age was 49.5 y and 3 of them had a smoking history. No survival 
      difference existed between fusion gene positive and negative patients 
      (36.7 vs.50.2 months, P = 0.21). CONCLUSION: The frequencies of ALK, ROS1 and RET 
      rearrangements are low in non-adenocarcinoma NSCLC patients. And their clinical 
      characteristics are similar to those in lung adenocarcinoma. Fusions of the above 
      3 genes are not prognostic factor for non-adnocarcinoma NSCLC patients.
FAU - Song, Zhengbo
AU  - Song Z
AD  - a Department of Medical Oncology , Zhejiang Cancer Hospital , Hangzhou , China.
AD  - b Key Laboratory Diagnosis & Treatment Technology of Thoracic Oncology , Zhejiang 
      province , Hangzhou , China.
FAU - Yu, Xinmin
AU  - Yu X
AD  - a Department of Medical Oncology , Zhejiang Cancer Hospital , Hangzhou , China.
AD  - b Key Laboratory Diagnosis & Treatment Technology of Thoracic Oncology , Zhejiang 
      province , Hangzhou , China.
FAU - Zhang, Yiping
AU  - Zhang Y
AD  - a Department of Medical Oncology , Zhejiang Cancer Hospital , Hangzhou , China.
AD  - b Key Laboratory Diagnosis & Treatment Technology of Thoracic Oncology , Zhejiang 
      province , Hangzhou , China.
LA  - eng
PT  - Journal Article
DEP - 20160916
PL  - United States
TA  - Cancer Biol Ther
JT  - Cancer biology & therapy
JID - 101137842
RN  - 0 (Proto-Oncogene Proteins)
RN  - EC 2.7.10.1 (Protein-Tyrosine Kinases)
RN  - EC 2.7.10.1 (Proto-Oncogene Proteins c-ret)
RN  - EC 2.7.10.1 (RET protein, human)
RN  - EC 2.7.10.1 (ROS1 protein, human)
SB  - IM
MH  - Adult
MH  - Carcinoma, Non-Small-Cell Lung/*genetics/mortality/pathology
MH  - Female
MH  - Gene Rearrangement
MH  - Humans
MH  - Lung Neoplasms/*genetics/mortality/pathology
MH  - Male
MH  - Middle Aged
MH  - Protein-Tyrosine Kinases/*genetics/metabolism
MH  - Proto-Oncogene Proteins/*genetics/metabolism
MH  - Proto-Oncogene Proteins c-ret/*genetics/metabolism
MH  - Survival Rate
PMC - PMC5710698
OTO - NOTNLM
OT  - ALK
OT  - RET
OT  - ROS1
OT  - frequency
OT  - fusion gene
OT  - non-small cell lung cancer
OT  - survival
EDAT- 2016/09/17 06:00
MHDA- 2018/07/26 06:00
PMCR- 2017/09/16
CRDT- 2016/09/17 06:00
PHST- 2016/09/17 06:00 [pubmed]
PHST- 2018/07/26 06:00 [medline]
PHST- 2016/09/17 06:00 [entrez]
PHST- 2017/09/16 00:00 [pmc-release]
AID - 1235660 [pii]
AID - 10.1080/15384047.2016.1235660 [doi]
PST - ppublish
SO  - Cancer Biol Ther. 2017 Nov 2;18(11):883-887. doi: 10.1080/15384047.2016.1235660. 
      Epub 2016 Sep 16.